Gain Therapeutics, a CataloniaBio & HealthTech member with headquarters in Lugano (Switzerland) and R&D departmant at Barcelona, signed an agreement collaboration with the US firm Zentalis Pharmaceuticals to discover new candidates for the treatment of cancer.
Zentalis is developing a promising pipeline of oncology best-in-class drugs. To identify new sites on target proteins for potential use in oncology they will use SEE-Tx® computational platform technology. SEE-Tx® applies a proprietary computational algorithm and supercomputer processing to the published 3D structure of proteins to discover new binding sites with the ability to modulate protein function.
Both Zentalis, which operates in New York and San Diego, and Gain are listed on the Nasdaq.
Photo: from left to right, Eric I. Richman, CEO of Gain Therapeutics, and Xavier Barril, CSO.
You may also be interested in:
Biotech firm Gain Therapeutics goes public on Nasdaq
Want to know more about Gain Therapeutics? We recommend this video of CataloniaBio & HealthTech interviewing them:
Comments